Physician profile
Heather Bruce
NPI 1447525886
$5,808.87
in general payments reported to CMS, 2019-2025
24 companies · $1,372 in 2025
The $1,372 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $104 · 2021: $90.05 · 2022: $340 · 2023: $343 · 2024: $3,416 · 2025: $1,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,200 · Food and Beverage: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,200.00 |
| Food and Beverage | $931.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $4,200.00 | 2024-2025 | Bovine Collagen |
| Abbvie INC. | $352.54 | 2020-2025 | Lo Loestrin Fe, Orilissa |
| Exeltis, USA INC. | $135.87 | 2022-2024 | Slynd |
| Daiichi Sankyo INC. | $134.36 | 2019-2023 | Injectafer |
| Organon LLC | $116.77 | 2022-2024 | Nexplanon |
| Novo Nordisk INC | $94.45 | 2019-2024 | Wegovy, Saxenda |
| Shield Therapeutics INC | $89.84 | 2024 | |
| Millicent US INC | $79.46 | 2024 | Intrarosa |
| Mayne Pharma Commercial LLC | $69.85 | 2022-2023 | |
| Astellas Pharma US INC | $66.19 | 2024-2025 | Veozah |
| Hologic Sales and Service, LLC | $57.34 | 2022-2024 | Novasure, Myosure Tissue Removal Device, Coolseal Generator |
| Pfizer INC. | $49.85 | 2023-2025 | |
| Therapeuticsmd, INC. | $48.45 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $46.19 | 2019-2020 | |
| Boston Scientific Corporation | $44.92 | 2021-2025 | Watchman Flx |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $42.48 | 2025 | Phexxi, Solosec, Phexx |
| Agile Therapeutics, INC. | $31.07 | 2021-2022 | |
| Minerva Surgical, INC | $30.46 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $24.46 | 2023 | Myfembree |
| Covidien LP | $24.05 | 2020 | |
| Molnlycke Health Care US, LLC | $22.43 | 2025 | Mepilex Border Post-Op Ag, Avance, Mepilex Border Post-Op |
| Bayer Healthcare Pharmaceuticals INC. | $21.80 | 2024 | |
| Dysis Medical, INC. | $14.93 | 2020 | |
| Amag Pharmaceuticals, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Bruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.